Table 1

Results of the recently presented randomized controlled trials evaluating thrombectomy vs medical management for ELVO

Trial†	Treatment arm	Good outcome at 90 days (%)*	p Value or 95% CI
MR CLEAN6	IAT	33	5.9 to 21.2
MR CLEAN6	Medical	19	5.9 to 21.2
ESCAPE7	IAT	53	<0.001
ESCAPE7	Medical	29	<0.001
EXTEND-IA8	IAT	71	0.01
EXTEND-IA8	Medical	40	0.01
SWIFT-PRIME9	IAT	60	<0.001
SWIFT-PRIME9	Medical	36	<0.001

*Modifed Rankin Score of 0–2.
†ESCAPE, Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial; MR CLEAN, Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands; SWIFT-PRIME, Solitaire FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke.
ELVO, emergent large vessel occlusion; IAT, intra-arterial therapy.